Mechanisms of lung cancer

Drug Discovery Today: Disease Mechanisms

Volumn 2, Issue 2, 2005, Pages 213-223

  Imyanitov, Evgeny N ^a   Kuligina, Ekatherina Sh ^a   Belogubova, Evgeniya V ^a   Togo, Alexandr V ^a   Hanson, Kaido P ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 7 HYDROXYSTAUROSPORINE; AE 941; ALVOCIDIB; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BORTEZOMIB; CELECOXIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLAVOPIRIDOL; FR 901228; GEFITINIB; IMATINIB; ISIS 2503; LAPATINIB; LONAFARNIB; MARIMASTAT; MATUZUMAB; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (3 MORPHOLINOPROPOXY) 6 QUINAZOLINYL]ACRYLAMIDE; OBLIMERSEN; PANITUMUMAB; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNINDEXED DRUG; VANDETANIB;

APOPTOSIS; AUTOCRINE EFFECT; CAUSE OF DEATH; CLINICAL TRIAL; DNA DAMAGE; DRUG TARGETING; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; INHERITANCE; LUNG CANCER; LUNG CARCINOGENESIS; NUCLEOTIDE SEQUENCE; PARACRINE SIGNALING; REVIEW; SIGNAL TRANSDUCTION; SMOKING;

EID: 33644525498     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2005.05.015     Document Type: Review

References (50)

1. R.N. Proctor Tobacco and the global lung cancer epidemic Nat. Rev. Cancer 1 2001 82-86
2. P.C. Hoffman et. al. Lung cancer Lancet 355 2000 479-485
3. S.S. Hecht Tobacco smoke carcinogens and lung cancer J. Natl. Cancer Inst. 91 1999 1194-1210
4. K. Junker et. al. Pathology of small-cell lung cancer J. Cancer Res. Clin. Oncol. 126 2000 361-368
5. R. Yesner Heterogeneity of so-called neuroendocrine lung tumors Exp. Mol. Pathol. 70 2001 179-182
6. E.M. Sellers et. al. Decreasing smoking behaviour and risk through CYP2A6 inhibition Drug Discov. Today 8 2003 487-493
7. M.J. Thun et. al. Tobacco use and cancer: An epidemiologic perspective for geneticists Oncogene 21 2002 7307-7325
8. C. Lerman W. Berrettini Elucidating the role of genetic factors in smoking behavior and nicotine dependence Am. J. Med. Genet. B Neuropsychiatr. Genet. 118 2003 48-54
9. E.P. Noble The DRD2 gene, smoking, and lung cancer J. Natl. Cancer Inst. 90 1998 343-345
10. X. Wu et. al. Genetic susceptibility to tobacco-related cancer Oncogene 23 2004 6500-6523
11. E.N. Imyanitov et. al. Searching for cancer-associated gene polymorphisms: Promises and obstacles Cancer Lett. 204 2004 3-14
12. M.R. Spitz et. al. Genetic susceptibility to lung cancer: The role of DNA damage and repair Cancer Epidemiol. Biomarkers Prev. 12 2003 689-698
13. J.E. Bailey-Wilson et. al. A major lung cancer susceptibility locus maps to chromosome 6q23-25 Am. J. Hum. Genet. 75 2004 460-474
14. D. Hanahan R.A. Weinberg The hallmarks of cancer Cell 100 2000 57-70
15. K.M. Fong et. al. Lung cancer. 9: Molecular biology of lung cancer: clinical implications Thorax 58 2003 892-900
16. E. Forgacs et. al. Molecular genetic abnormalities in the pathogenesis of human lung cancer Pathol. Oncol. Res. 7 2001 6-13
17. D. Masuya et. al. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients Br. J. Cancer 90 2004 1555-1562
18. F.J. Kaye Molecular biology of lung cancer Lung Cancer 34 Suppl. 2 2001 S35-S41
19. D.S. Schrump D.M. Nguyen Targets for molecular intervention in multistep pulmonary carcinogenesis World J. Surg. 25 2001 174-183
20. H. Wikman et. al. CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer Genes Chromosomes Cancer 42 2005 193-199
21. F. Ciardiello et. al. The role of EGFR inhibitors in nonsmall cell lung cancer Curr. Opin. Oncol. 16 2004 130-135
22. A. Burton What went wrong with Iressa? Lancet Oncol. 3 2002 708
23. T.J. Lynch et. al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129-2139
24. J.G. Paez et. al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy Science 304 2004 1497-1500
25. W. Pao et. al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc. Natl. Acad. Sci. USA 101 2004 13306-13311
26. H. Shigematsu et. al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J. Natl. Cancer Inst. 97 2005 339-346
27. B. Vogelstein K.W. Kinzler Cancer genes and the pathways they control Nat. Med. 10 2004 789-799
28. P. Stephens et. al. Lung cancer: Intragenic ERBB2 kinase mutations in tumours Nature 431 2004 525-526
29. P.C. Ma et. al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer Cancer Res. 65 2005 1479-1488
30. J.R. Fischer H. Lahm Validation of molecular and immunological factors with predictive importance in lung cancer Lung Cancer 45 Suppl. 2 2004 S151-S161
31. P. Fernandez et. al. Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations Oncogene 23 2004 5084-5091
32. M. Nishioka et. al. MYO18B, a candidate tumor suppressor gene at chromosome 22q12.1, deleted, mutated, and methylated in human lung cancer Proc. Natl. Acad. Sci. USA 99 2002 12269-12274
33. F.M. Kong et. al. M6P/IGF2R is mutated in squamous cell carcinoma of the lung Oncogene 19 2000 1572-1578
34. G. Mariatos et. al. Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer Cancer Res. 63 2003 7185-7189
35. M. Kishimoto et. al. Mutations and deletions of the CBP gene in human lung cancer Clin. Cancer Res. 11 2005 512-519
36. P. Maione et. al. The role of targeted therapy in non-small cell lung cancer Crit. Rev. Oncol. Hematol. 51 2004 29-44
37. N. Murray et. al. Targeted molecules in small cell lung cancer Semin. Oncol. 31 1 Suppl. 1 2004 106-111
38. S. Korfee et. al. New targeted treatments in lung cancer - overview of clinical trials Lung Cancer 45 Suppl. 2 2004 S199-S208
39. S.S. Sridhar F.A. Shepherd Targeting angiogenesis: A review of angiogenesis inhibitors in the treatment of lung cancer Lung Cancer 42 Suppl. 1 2003 S81-S91
40. A. Rossi et. al. The role of new targeted therapies in small-cell lung cancer Crit. Rev. Oncol. Hematol. 51 2004 45-53
41. T. Hoang et. al. Novel therapies for lung cancer Surg. Oncol. 11 2002 229-241
42. P.C. Mack et. al. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer Lung Cancer 41 Suppl. 1 2003 S89-S96
43. S. Zochbauer-Muller et. al. Aberrant DNA methylation in lung cancer: biological and clinical implications Oncologist 7 2002 451-457
44. C. Moon et. al. Current status of gene therapy for lung cancer and head and neck cancer Clin. Cancer Res. 9 2003 5055-5067
45. S.S. Sridhar et. al. Inhibitors of epidermal-growth-factor receptors: A review of clinical research with a focus on non-small-cell lung cancer Lancet Oncol. 4 2003 397-406
46. K.M. Hege D.P. Carbone Lung cancer vaccines and gene therapy Lung Cancer 41 Suppl. 1 2003 S103-S113
47. R. Ahuja et. al. Lung cancer: The oncologist's role in smoking cessation Semin. Oncol. 30 2003 94-103
48. A.J. Alberg J.M. Samet Epidemiology of lung cancer Chest 123 1 Suppl. 2003 21S-49S
49. J.C. Soria et. al. Chemoprevention of lung cancer Lancet Oncol. 4 2003 659-669
50. R. Rosell et. al. Molecular predictors of response to chemotherapy in lung cancer Semin. Oncol. 31 1 Suppl. 1 2004 20-27